Education
About Us
Working with TipRanks
Follow Us
Fresenius SE & Co (FSNUY)
OTHER OTC:FSNUY
Top Page
Fresenius SE & Co
(OTC:FSNUY)
62Neutral
Fresenius SE & Co (FSNUY) vs. S&P 500 (SPY)
Market Cap
$24.28B
Dividend YieldN/A
Average Volume (3M)1.94K
Price to Earnings (P/E)47.4
Beta (1Y)0.29
Revenue Growth-38.44%
EPS Growth-243.76%
CountryUS
Employees177,091
SectorHealthcare
Sector Strength72
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.23
Shares Outstanding2,252,949,200
10 Day Avg. Volume0
30 Day Avg. Volume1,941
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.55
Price to Cash Flow (P/CF)3.10
P/FCF Ratio5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.50Price Target Upside6.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Fresenius SE & Co Business Overview & Revenue Model
Company DescriptionFresenius SE & Co. KGaA is a global healthcare group based in Bad Homburg, Germany. The company operates through four main business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. Fresenius Kabi specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Fresenius Helios is Europe’s largest private hospital operator, while Fresenius Vamed provides services for hospitals and other healthcare facilities.
How the Company Makes MoneyFresenius SE & Co. KGaA generates revenue through its diversified healthcare operations. Fresenius Medical Care contributes significantly by providing dialysis products and services, both directly to patients and through healthcare providers. Fresenius Kabi earns revenue from the sale of pharmaceuticals and medical devices, focusing on hospitals and outpatient sectors. Fresenius Helios generates income from operating private hospitals, offering inpatient and outpatient medical services. Fresenius Vamed earns by providing project management, consulting, and operational management services for healthcare facilities. The company’s earnings are further supported by strategic partnerships and collaborations in the healthcare sector, enhancing its service and product offerings.
Fresenius SE & Co Financial Statement Overview
Summary
Fresenius SE & Co exhibits reasonable operational efficiency with strong cash flow metrics but faces challenges with declining revenue and negative profitability. The balance sheet remains robust with manageable leverage. While cash flows are favorable, sustaining profitability is crucial for improving overall financial health.Income Statement
The company shows declining revenue from the previous year, indicating potential challenges in maintaining sales momentum. Gross profit margin stands at 23.81% TTM, highlighting reasonable cost management, but the net profit margin is negative due to recent losses. EBITDA margin is healthy at 13.02%, showing operational efficiency. However, the negative net income raises concerns about profitability sustainability.55
Neutral
Balance Sheet
The debt-to-equity ratio is 0.71, indicating a balanced leverage position. Return on Equity is negative due to current losses, which is concerning. The equity ratio of 44.45% TTM suggests a strong equity base. Overall, the balance sheet shows stability but is affected by profitability concerns.60
Neutral
Cash Flow
Free cash flow is positive and the free cash flow to net income ratio is strong due to negative net income, indicating cash flow resilience despite profitability issues. Operating cash flow to net income ratio is positive, showcasing efficient cash generation capabilities. However, declining free cash flow growth is a potential area of concern.70
Positive
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 22.21B | 22.30B | 40.84B | 37.52B | 36.28B | 35.41B | Gross Profit |
| 5.29B | 5.06B | 10.72B | 10.31B | 10.32B | 10.35B | EBIT |
| 1.40B | 1.14B | 3.51B | 4.16B | 4.38B | 4.63B | EBITDA |
| 2.89B | 2.73B | 3.10B | 6.95B | 7.19B | 7.25B | Net Income Common Stockholders |
| -383.00M | -594.00M | 2.12B | 2.82B | 2.82B | 3.03B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.29B | 2.56B | 2.35B | 2.75B | 2.00B | 1.79B | Total Assets |
| 45.28B | 45.28B | 76.42B | 71.96B | 66.65B | 67.01B | Total Debt |
| 15.83B | 15.83B | 27.76B | 27.16B | 25.91B | 27.26B | Net Debt |
| 13.54B | 13.54B | 25.59B | 24.55B | 24.08B | 25.60B | Total Liabilities |
| 25.63B | 25.63B | 44.20B | 42.67B | 40.62B | 40.43B | Stockholders Equity |
| 19.00B | 19.00B | 20.41B | 19.00B | 16.95B | 16.78B |
| Cash Flow | Free Cash Flow | ||||
| 2.44B | 3.32B | 2.28B | 3.03B | 4.14B | 1.80B | Operating Cash Flow |
| 3.29B | 4.46B | 4.20B | 5.08B | 6.55B | 4.26B | Investing Cash Flow |
| -2.08B | -3.19B | -2.61B | -2.82B | -3.01B | -4.86B | Financing Cash Flow |
| -2.33B | -1.38B | -1.60B | -1.45B | -3.12B | -484.00M |
Fresenius SE & Co Technical Analysis
Positive
10.83
Price Trends
10.09
Positive
9.47
Positive
9.10
Positive
Market Momentum
0.22
Positive
60.34
Neutral
74.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 10.83 is above the 20-day moving average (MA) of 10.74, above the 50-day MA of 10.09, and above the 200-day MA of 9.10, indicating a bullish trend. The MACD of 0.22 indicates Positive momentum. The RSI at 60.34 is Neutral, neither overbought nor oversold. The STOCH value of 74.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.
Fresenius SE & Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $139.13B | 46.96 | 15.26% | 0.89% | 10.23% | -5.74% | |
79 Outperform | $226.88B | 17.13 | 30.95% | 1.71% | 4.59% | 134.50% | |
76 Outperform | $65.32B | 37.79 | 6.92% | 1.71% | 5.89% | 42.05% | |
65 Neutral | $147.28B | 38.92 | 7.57% | 0.52% | -13.50% | -17.25% | |
62 Neutral | $24.28B | 47.42 | 5.47% | ― | -38.44% | -243.76% | |
54 Neutral | $17.31B | 136.07 | -9.24% | 2.73% | -14.00% | -184.82% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% |
* Healthcare Sector Average
Performance Comparison
FSNUY
Fresenius SE & Co
10.83
4.11
61.16%
ABT
Abbott Laboratories
130.82
20.97
19.09%
BAX
Baxter International
33.75
-8.67
-20.44%
BDX
Becton Dickinson
227.50
-12.36
-5.15%
DHR
Danaher
205.85
-40.77
-16.53%
SYK
Stryker
364.50
12.27
3.48%
Fresenius SE & Co Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: 12.81% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance, strategic restructuring, and resumed dividend payments, indicating overall progress. However, challenges in China, the end of energy relief payments, and competitive pressures in Biopharma create headwinds.Highlights
Strong Financial Performance in 2024
Fresenius achieved high single-digit organic revenue growth, with EBIT growing even faster in double digits. Key growth drivers included MedTech, Nutrition, and Biopharma, with Biopharma showing 76% year-over-year growth.
Significant Margin and Cash Flow Improvement
The company improved its EBIT margins by 180 basis points over the past two years and achieved a strong EPS growth of 14% in 2024, compared to a 13% decline in 2022. Operating cash flow neared €1 billion in the fourth quarter.
Successful Portfolio Restructuring
Fresenius successfully concluded several strategic measures, including divesting non-core assets, deconsolidating Fresenius Medical Care, and exiting Vamed, resulting in a simpler and more focused company.
Resumption of Dividend Payments
Fresenius announced a proposed dividend of €1 per share for 2024, reflecting financial strength and a commitment to shareholder value.
Lowlights
Challenges in China
Fresenius faces challenges due to the national volume-based procurement (NVBP) program in China, which affects the performance of key products like keto. The company does not anticipate a substantive change to the operating environment in the short term.
Impact of Energy Relief Payment Ending
Helios Germany faces a tough year-on-year comparison due to the absence of a €140 million energy relief payment received in 2023, creating headwinds for 2025.
Regulatory and Market Challenges for Biopharma
Biopharma faces competitive market dynamics and regulatory approval processes, impacting the timing and scale of product launches like ustekinumab and denosumab.
Company Guidance
During the call, Fresenius provided a comprehensive outlook for 2025, emphasizing continued momentum in financial and operational performance. The guidance for the fiscal year 2025 includes organic revenue growth of 4% to 6% and EBIT growth of 3% to 7%, both at constant currency. The company highlighted significant achievements in 2024, including surpassing €470 million in structural cost improvements and achieving high single-digit organic revenue growth, with EBIT expanding even faster in double digits. Key growth drivers were the MedTech, Nutrition, and Biopharma segments, with Biopharma particularly standing out with 76% year-over-year growth. The company also noted Helios' consistent revenue performance and a substantial improvement in EPS, moving from a 13% decline in 2022 to 14% growth in 2024. The guidance reflects a confident outlook, with a focus on executing its "Rejuvenate" strategy and achieving further operational efficiencies and market expansion.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.